CClinicalTrials.gg
Active, not recruitingNCT07336498MTA/CBCTUpdated Jan 13, 2026

Clinical Evaluation and Cone Beam Computed Tomography Analysis of Different Biomaterials for Apexogenesis of Immature Permanent Molars

An interventional study of Vital pulp therapy of immature permanent teeth in Vital Pulp Therapy in Young Permanent Tooth, sponsored by Al-Azhar University. Active, not recruiting at 1 site in Egypt. Open to participants aged 7 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as active, not recruiting.
  • Registered 8 months after the study started (first participant enrolled Mar 2025, registered Nov 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
7 Years to 10 Years
Sex
All
01

Study summary

The present study will be conducted to clinically evaluation and cone beam computed tomography analysis of amniotic membrane, putty mineral trioxide aggregate and biodentine as therapeutic agents for apexogenesis of immature permanent molars

Read the detailed description

An immature permanent tooth is defined as, a newly erupted permanent tooth with incomplete root apex formation. Since root development is completed in 2-3 years after tooth eruption into the oral cavity, loss of pulp vitality in the immature permanent tooth affected by caries, traumatic injury, or other causes creates major problems. The primary goal of pulp therapy is to maintain the integrity of the teeth while maintaining the vitality of the pulp, especially in young permanent teeth with immature roots to enhance root dentin formation. An increasingly popular therapy option for pulp damage in immature permanent molars is apexogenesis. Vital pulp therapy involves the complete removal of the coronal pulp and the placement of an acceptable material into the pulp chamber. With the invention of calcium silicate material namely mineral trioxide aggregate (MTA), it became preferred to calcium hydroxide in the treatment of exposed pulp. MTA demonstrated excellent biocompatibility, low solubility, outstanding sealing properties and antibacterial effect. However, MTA has some limitations regarding the long setting time and difficult handling. Premixed calcium silicate cements were developed to facilitate manipulation with no need for mixing, such as using the putty formulation which allows better handling with a thicker consistency Additionally, Biodentine was introduced as a tricalcium silicate-based bioceramic, with comparable physical properties to dentine, thus, it is also called dentine replacement material and has applications like those of MTA. Considering the limitations of MTA, biodentine has been developed with enhanced physicochemical properties such as a fast-setting time with an initial setting time between 9 and 12 minutes due to the presence of calcium chloride. Its short setting time allows restoration to be made in one session with easier chairside handling than MTA. Recently, novel biologically based material has been developed from the innermost layer of the placenta with highly rich stem cell reservoirs and is called amniotic membrane. The amniotic membrane is rich in growth factors, various types of collagens (such as types I, III, IV, V, and VII), along with proteoglycans, elastin and hyaluronic acid. It possesses a range of beneficial properties, including anti-inflammatory, antimicrobial and analgesic which make it a unique option for wound healing, providing a supportive environment that promotes the survival and proliferation of mesenchymal progenitor cells. In dentistry, researchers supported its application in regenerative endodontic therapy by providing a growth factors that promote stem cell growth and formation of a new dentine-pulp complex. Therefore, in the present study, clinical and radiographic evaluation will be done to assess the effectiveness of different biomaterials in managing immature permanent tooth with pulp exposure.

02

Conditions studied

  • Vital Pulp Therapy in Young Permanent Tooth
03

In context

Lead sponsor

Al-Azhar University is the lead sponsor of 505 studies on the registry; 167 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Healthy patients without any systemic disease aged 7 to 10 years old.
  • Vital immature permanent molars with deep carious lesions.
  • Restorable tooth
  • No clinical signs and symptoms of irreversible pulpitis including spontaneous pain, tenderness to percussion, swelling or sinus tract.
  • No radiographic evidence of periapical abscess, internal or external resorption.

Exclusion criteria

Exclusion Criteria:

  • Patients with known allergies to any of the dental materials to be used.
  • Bleeding could not be controlled within 5 minutes after complete pulpotomy
  • Teeth with root fractures
  • Carious furcation involvement
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Biodentine will be placed directly in the pulp chamber

    Procedure: Vital pulp therapy of immature permanent teeth

  • Experimental
    Previously trimmed amniotic membrane will be placed directly in the pulp chamber

    Procedure: Vital pulp therapy of immature permanent teeth

  • Other
    Putty MTA will be placed directly in the pulp chamber

    Procedure: Vital pulp therapy of immature permanent teeth

Interventions

  • ProcedureVital pulp therapy of immature permanent teeth

    Conventional access cavity will be done with a high-speed bur using copious water spray. The coronal pulp amputation will be performed using a sharp spoon excavator. In order to achieve hemostasis sterilized cotton pellet moistened with sterile saline will be placed over the pulp's stumps for 5 minutes, followed by application of the therapeutic agent. The prepared cavities of all molars will be sealed with a layer of glass ionomer over the therapeutic agents and subsequently will be covered with composite resin restoration.

06

What researchers measure

Primary outcomes

  1. Clinical outcomes

    Clinical assessment of the treated immature molars in each follow up period as follow: 1. Presence or Absence of pain or sensitivity to percussion. 2. Presence or absence of any evidence of swelling, or sinus tract. 3. Presence or absence of excessive mobility of the treated teeth .

    Time frame: Base line, 7 days, 3 months, 6 months , 12 months

Secondary outcomes

  1. Radiographic assessment of root length by CBCT

    The CBCT scanning was performed immediately after treatment to serve as the baseline and at 12 months follow-up periods to evaluate changes in the root for each tooth in all groups. Root length: the sagittal section was used to measure the root length for each root using the CBCT ruler to draw a line from the center point of the line connecting CEJ to the most apical point in the center of the root apex. the percentage of increase in root length of the immature permanent molar was calculated by the following formula: (12 months value-baseline value)/(Preoperative value) ×100

    Time frame: Baseline (immediately post-operative ) and 12 months post-operative

  2. Radiographic assessment of diameter of apical foramen by CBCT

    At the most apical point buccolingually in the sagittal view of the CBCT, the diameter of the apical foramen was measured using the CBCT ruler for each root of the immature permanent tooth. The percentage reduction of the apical diameter was calculated using this formula: (baseline value-12 months value)/(Preoperative value)×100

    Time frame: Baseline (immediately post-operative) and 12 months post-operative)

  3. Radiographic assessment of radiographic root area by CBCT

    Using the CBCT polygon selection tool at the sagittal section and below a straight line marking the cementoenamel junction, the root area was outlined from the surrounding periodontal environment. The pulp space area was then calculated using the same technique, tracing the reference points around the pulp space with the polygon tool. Finally, the pulp space area was subtracted from the outer root area to determine the radiographic root area. The percentage of increase in radiographic root area of the immature permanent molar was calculated by the following formula: (12 months value-baseline value)/(Preoperative value) ×100

    Time frame: Baseline(immediately post-operative) and at 12 months post-operative

07

Study locations

1 site
  • Faculty of Dentistry, Al-Azhar University, Cairo (Boys Branch)
    Cairo, Egypt
08

References and documents

Publications

  • Duncan HF, Nagendrababu V, El-Karim IA, Dummer PMH. Outcome measures to assess the effectiveness of endodontic treatment for pulpitis and apical periodontitis for use in the development of European Society of Endodontology (ESE) S3 level clinical practice guidelines: a protocol. Int Endod J. 2021 May;54(5):646-654. doi: 10.1111/iej.13501. Epub 2021 Mar 15. PubMed 33630330 ↗
  • Dentistry AAoP. Pulp therapy for primary and immature permanent teeth. The Reference Manual of Pediatric Dentistry Chicago, Ill: American Academy of Pediatric Dentistry. 2021;399407.
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07336498
Lead sponsor
Al-Azhar University
Responsible party
Sara Mohamed Ezz Eldeen Ghareep (Assistant lecturer, Al-Azhar University) — Principal investigator
First posted
Jan 13, 2026
Start date
Mar 1, 2025
Primary completion
Mar 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Jan 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion